Clinical trials: SCLC
Efficacy
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
In this randomized, double-blind, multicenter, phase III similarity study, treatment naive, EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (ns-NSCLC) patients were enrolled…
- Trial name
- NCT05427305
- Testing
- TAB008, Bevacizumab
- Where
- China
- Volunteers
- 549 people
- Sponsor
- BioDlink Biopharm Co., Ltd.
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.
- Trial name
- NCT00285675
- Testing
- DN-101 (calcitriol) - Drug
- Where
- 13 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Novacea
Carcinoma, Non-Small-Cell Lung
GIOTRIF rPMS in Korean Patients With NSCLC
To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Trial name
- NCT02285361
- Testing
- GIOTRIF 20mg, GIOTRIF 40mg, GIOTRIF 30mg
- Where
- South Korea
- Volunteers
- 1,272 people
- Sponsor
- Boehringer Ingelheim
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20…
- Trial name
- NCT06616766
- Testing
- YH42946
- Where
- 8 sites in United States, South Korea
- Volunteers
- 201 people
- Sponsor
- Yuhan Corporation
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Anemia, Multiple Myeloma
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with cancer receiving chemotherapy, and to investigate…
- Conditions
- Anemia, Multiple Myeloma, Lymphoma, Breast Cancer
- Trial name
- NCT00270166
- Testing
- epoetin alfa
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Carcinoma, Non Small Cell Lung
Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
- Trial name
- NCT00191256
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for…
- Trial name
- NCT00050973
- Testing
- bexarotene
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 623 people
- Sponsor
- Eisai Inc.
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Malignant Neoplasm
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors.
- Trial name
- NCT06385925
- Testing
- TSN1611
- Where
- 19 sites in United States, China
- Volunteers
- 440 people
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
Non-small Cell Lung Cancer
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated…
- Trial name
- FOCAL (NCT02318368)
- Testing
- Ficlatuzumab, Erlotinib
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC)…
- Trial name
- NCT01531790
- Testing
- Carboplatin, Pemetrexed, Endostar
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
- Trial name
- NCT04025879
- Testing
- Nivolumab, Carboplatin, Cisplatin
- Where
- 108 sites in United States, Argentina and 20 more
- Volunteers
- 461 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with…
- Trial name
- NCT06069570
- Testing
- KB-GDT-01
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Kiromic BioPharma Inc.
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe…
- Conditions
- Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03916627
- Testing
- cemiplimab, Platinum Doublet, fianlimab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Long-term Observation PMS for Afatinib
In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination.
- Trial name
- NCT02131259
- Testing
- Afatinib dimaleate
- Where
- 432 sites in Japan
- Volunteers
- 1,605 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01792479
- Testing
- BIND-014
- Where
- 17 sites in United States, Russia
- Volunteers
- 64 people
- Sponsor
- BIND Therapeutics
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.